Form 4: Apogee Therapeutics' Chief Medical Officer Carl Dambkowski Sells Shares

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold a portion of his holdings in the company's common stock on September 4, 2024, under a pre-arranged trading plan.

Summary

• Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, sold shares of the company's common stock on September 4, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 27, 2023.
• Two transactions occurred: one involving 5,878 shares at a weighted average price of $47.49, and another involving 787 shares at a weighted average price of $48.06.
• Following these transactions, Dambkowski directly owns 280,793 shares of Apogee Therapeutics.
• The weighted average price for the first transaction ranged from $46.79 to $47.77, and for the second transaction, it ranged from $47.80 to $48.42.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing trading plan, which is a routine activity.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often related to personal financial planning. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on insider information.

Stakeholder Impact

• The stock sale by a high-ranking officer could be perceived negatively by some shareholders, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates